Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 13:10:33 UTC |
---|
Update Date | 2022-11-23 22:29:16 UTC |
---|
HMDB ID | HMDB0254052 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Levomedetomidine |
---|
Description | Medetomidine, also known as domitor or MPV-785, belongs to the class of organic compounds known as o-xylenes. These are aromatic compounds that contain a o-xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups at the 1- and 2-positions. Medetomidine is a synthetic compound used as a surgical anesthetic and analgesic. Medetomidine is a very strong basic compound (based on its pKa). Medetomidine is a potentially toxic compound. The marketed product is a racemic mixture of two stereoisomers from which dexmedetomidine is the main active isomer. In Canada, medetomidine is distributed by Novartis Animal Health. The drug has been developed by Orion Pharma. Medetomidine is an intravenously available alpha-2 adrenergic agonist. In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. It is normally found as its hydrochloride salt, medetomidine hydrochloride. This compound has been identified in human blood as reported by (PMID: 31557052 ). Levomedetomidine is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Levomedetomidine is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | CC(C1=CN=CN1)C1=CC=CC(C)=C1C InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15) |
---|
Synonyms | Value | Source |
---|
(+-)-4-(alpha,2,3-Trimethylbenzyl)imidazole | ChEBI | Medetomidina | ChEBI | Medetomidinum | ChEBI | Domitor | Kegg | (+-)-4-(a,2,3-Trimethylbenzyl)imidazole | Generator | (+-)-4-(Α,2,3-trimethylbenzyl)imidazole | Generator | Levomedetomidine | MeSH | Medetomidine hydrochloride | MeSH | Hydrochloride, medetomidine | MeSH | MPV-785 | MeSH | MPV 785 | MeSH |
|
---|
Chemical Formula | C13H16N2 |
---|
Average Molecular Weight | 200.2795 |
---|
Monoisotopic Molecular Weight | 200.131348522 |
---|
IUPAC Name | 5-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole |
---|
Traditional Name | medetomidine |
---|
CAS Registry Number | Not Available |
---|
SMILES | CC(C1=CN=CN1)C1=CC=CC(C)=C1C |
---|
InChI Identifier | InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15) |
---|
InChI Key | CUHVIMMYOGQXCV-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as o-xylenes. These are aromatic compounds that contain a o-xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups at the 1- and 2-positions. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Xylenes |
---|
Direct Parent | o-Xylenes |
---|
Alternative Parents | |
---|
Substituents | - O-xylene
- Heteroaromatic compound
- Imidazole
- Azole
- Azacycle
- Organoheterocyclic compound
- Organic nitrogen compound
- Organopnictogen compound
- Hydrocarbon derivative
- Organonitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
levomedetomidine,1TMS,isomer #1 | CC1=CC=CC(C(C)C2=CN=CN2[Si](C)(C)C)=C1C | 1906.8 | Semi standard non polar | 33892256 | levomedetomidine,1TMS,isomer #1 | CC1=CC=CC(C(C)C2=CN=CN2[Si](C)(C)C)=C1C | 1869.0 | Standard non polar | 33892256 | levomedetomidine,1TMS,isomer #1 | CC1=CC=CC(C(C)C2=CN=CN2[Si](C)(C)C)=C1C | 2175.9 | Standard polar | 33892256 | levomedetomidine,1TBDMS,isomer #1 | CC1=CC=CC(C(C)C2=CN=CN2[Si](C)(C)C(C)(C)C)=C1C | 2164.1 | Semi standard non polar | 33892256 | levomedetomidine,1TBDMS,isomer #1 | CC1=CC=CC(C(C)C2=CN=CN2[Si](C)(C)C(C)(C)C)=C1C | 2041.1 | Standard non polar | 33892256 | levomedetomidine,1TBDMS,isomer #1 | CC1=CC=CC(C(C)C2=CN=CN2[Si](C)(C)C(C)(C)C)=C1C | 2302.3 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Levomedetomidine GC-MS (Non-derivatized) - 70eV, Positive | splash10-001r-3900000000-6ddf8df46b60cbbf97bc | 2017-08-28 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Levomedetomidine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 10V, Positive-QTOF | splash10-0udi-0290000000-a37775586d59da8a5c1d | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 20V, Positive-QTOF | splash10-0uk9-1950000000-1f473c29f9a4392cf069 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 40V, Positive-QTOF | splash10-0a4i-1900000000-05caba97ecbe584d9c19 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 10V, Negative-QTOF | splash10-0002-0900000000-b4978ed90cadc637e3fb | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 20V, Negative-QTOF | splash10-0002-1900000000-b7da7a8cb234743e8c21 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 40V, Negative-QTOF | splash10-0awc-4900000000-2ac7ce450e11fc5753d7 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 10V, Positive-QTOF | splash10-0udi-1690000000-25384c2b2a9cdfdde94d | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 20V, Positive-QTOF | splash10-0002-9820000000-afacb1a5733ec680ba25 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 40V, Positive-QTOF | splash10-016u-9800000000-4abb53cf4197dbae49a2 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 10V, Negative-QTOF | splash10-0002-1900000000-bb36123876a779fd4c00 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 20V, Negative-QTOF | splash10-016r-9700000000-af5360fd2dd430780f16 | 2021-10-12 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Levomedetomidine 40V, Negative-QTOF | splash10-0690-7900000000-3cbf817f1a6352e6258d | 2021-10-12 | Wishart Lab | View Spectrum |
|
---|